PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.29%
EBIT growth below 50% of AXSM's 23.84%. Michael Burry would suspect deeper competitive or cost structure issues.
3.29%
Operating income growth under 50% of AXSM's 35.57%. Michael Burry would be concerned about deeper cost or sales issues.
27.01%
Net income growth 1.25-1.5x AXSM's 19.26%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
26.90%
EPS growth 1.25-1.5x AXSM's 20.49%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
26.90%
Diluted EPS growth 1.25-1.5x AXSM's 20.49%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.31%
OCF growth under 50% of AXSM's 25.25%. Michael Burry might suspect questionable revenue recognition or rising costs.
3.31%
FCF growth under 50% of AXSM's 25.25%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.36%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-12.36%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-12.36%
Negative 3Y OCF/share CAGR while AXSM stands at 23.58%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
44.63%
Positive 10Y CAGR while AXSM is negative. John Neff might see a substantial advantage in bottom-line trajectory.
44.63%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
44.63%
3Y net income/share CAGR above 1.5x AXSM's 11.48%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
-80.42%
Negative equity/share CAGR over 10 years while AXSM stands at 360.64%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-80.42%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-80.42%
Negative 3Y equity/share growth while AXSM is at 280.02%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.02%
Asset growth well under 50% of AXSM's 7.23%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-16.23%
We have a declining book value while AXSM shows 35.76%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
14.30%
Debt growth far above AXSM's 2.81%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.62%
We cut SG&A while AXSM invests at 7.86%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.